AI Article Synopsis

  • Biosimilars like MYL-1701P, a version of aflibercept, offer potentially cheaper options for treating diabetic macular edema (DME), but their efficacy and safety compared to the original have not been fully studied.
  • A randomized double-masked trial across multiple countries involved 355 participants with DME to compare MYL-1701P and aflibercept, focusing on vision improvement and side effects over a year.
  • Results showed similar improvements in visual acuity between the two treatments after 8 weeks, with MYL-1701P achieving an adjusted mean difference of just 0.04 letters from aflibercept, indicating comparable effectiveness.

Article Abstract

Importance: Biosimilars may be lower-cost alternatives to originator biologic products, potentially offering expanded access or reduced economic burden, but have not been evaluated with aflibercept in diabetic macular edema (DME).

Objective: To compare efficacy and safety of MYL-1701P, an aflibercept biosimilar, with reference aflibercept (Eylea [Regeneron]) in DME.

Design, Setting, And Participants: This was a double-masked, randomized clinical trial that included participants at 77 centers across the US, Europe, Japan, and India. Included in the analysis were individuals 18 years and older with type 1 or type 2 diabetes with central DME and best-corrected visual acuity (BCVA) letter score of 73 to 38 in the study eye using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Study data were analyzed from October to December 2021.

Interventions: Formulations of MYL-1701P (0.5-mg vial) or reference aflibercept every 4 weeks for 5 consecutive intravitreal injections, followed by every 8 weeks through week 52.

Main Outcomes And Measures: The primary outcome was the adjusted difference in least squares mean (SE) change from baseline BCVA letter score at week 8 with an equivalence margin of -3 to +3 letters. Secondary outcomes included change in central subfield thickness (CST), BCVA, number of injections over 52 weeks, incidence of adverse events (AEs), and antidrug antibodies (ADAs).

Results: A total of 355 participants (mean [SD] age, 62.2 [9.2] years; 216 male [60.8%]) were randomized to MYL-1701P (179 participants [50.4%]) and aflibercept (176 participants [49.6%]). At week 8, mean (SE) change in BCVA was 6.60 (0.55) letters vs 6.56 (0.55) letters in the MYL-1701P vs aflibercept groups. The adjusted mean difference of 0.04 letters (90% CI, -1.16 to 1.24 letters) met the primary outcome. At week 8, mean (SE) change in CST was -112 (7) μm vs -124 (7) μm in the MYL-1701P vs aflibercept groups (adjusted mean difference, 12 μm; 90% CI, -3 to 26 μm). The incidence of treatment-emergent AEs in the MYL-1701P and aflibercept arms were ocular (30.9% [55 of 178] vs 29.5% [52 of 176]), serious ocular (0.6% [1 of 178] vs 1.1% [2 of 176]), nonocular (65.2% [116 of 178] vs 65.3% [115 of 176]), and serious nonocular (16.9% [30 of 178] vs 11.9% [21 of 176]). The mean (SD) total number of injections was 8.4 (2.1) vs 8.7 (1.8) in the MYL-1701P vs aflibercept groups. The incidence of treatment-induced or treatment-boosted ADAs was 2.8% (5 of 177) vs 5.7% (10 of 176) in the MYL-1701P vs aflibercept arms.

Conclusions And Relevance: MYL-1701P demonstrated clinical equivalence in regard to efficacy, with comparable safety and immunogenicity, to reference aflibercept. These findings support use of MLY-1701P as an alternative to reference aflibercept.

Trial Registration: ClinicalTrials.gov Identifier: NCT03610646.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11393752PMC
http://dx.doi.org/10.1001/jamaophthalmol.2024.3458DOI Listing

Publication Analysis

Top Keywords

myl-1701p aflibercept
24
reference aflibercept
16
aflibercept
13
adjusted difference
12
aflibercept groups
12
myl-1701p
10
aflibercept biosimilar
8
aflibercept diabetic
8
diabetic macular
8
macular edema
8

Similar Publications

Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial.

JAMA Ophthalmol

October 2024

Clinical Development & Medical Affairs Department, Biocon Biologics Ltd, Bangalore, Karnataka, India.

Article Synopsis
  • Biosimilars like MYL-1701P, a version of aflibercept, offer potentially cheaper options for treating diabetic macular edema (DME), but their efficacy and safety compared to the original have not been fully studied.
  • A randomized double-masked trial across multiple countries involved 355 participants with DME to compare MYL-1701P and aflibercept, focusing on vision improvement and side effects over a year.
  • Results showed similar improvements in visual acuity between the two treatments after 8 weeks, with MYL-1701P achieving an adjusted mean difference of just 0.04 letters from aflibercept, indicating comparable effectiveness.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!